Beyond Air (NASDAQ:XAIR – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Valuation and Earnings
This table compares Beyond Air and InspireMD’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Beyond Air||$870,000.00||110.07||-$55.82 million||($1.95)||-1.55|
|InspireMD||$5.17 million||13.53||-$18.49 million||($1.95)||-1.69|
InspireMD has higher revenue and earnings than Beyond Air. InspireMD is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
Risk and Volatility
Beyond Air has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
This table compares Beyond Air and InspireMD’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Beyond Air and InspireMD, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beyond Air presently has a consensus target price of $12.25, suggesting a potential upside of 305.63%. InspireMD has a consensus target price of $5.20, suggesting a potential upside of 57.58%. Given Beyond Air’s higher probable upside, equities research analysts clearly believe Beyond Air is more favorable than InspireMD.
Beyond Air beats InspireMD on 7 of the 13 factors compared between the two stocks.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.